In addition to developing and sharing our clinical pipeline in allergy, Worg intends to forge strategic partnership to co-develop innovative treatments beyond allergy immunotherapy.


Worg is actively seeking license-in opportunities of late-stage or commercial assets for the Greater China territories, as well as innovative early-stage projects with global rights.

You can benefit from a deep collective knowledge of late-stage pharmaceutical development, as well as the market access to China and the abundant capital resource.

To find out more partnering opportunities, please email to info@worgpharma.com


We expect partners with strong capability of late-stage clinical development and commercialization to work with Worg outside Greater China.

Worg plans to partner or license out the territory rights of WP1048, WP1049 and WP1073 in Europe, USA and ROW with flexible cooperation. 


Worg has established strong connection with several academic institutes, e.g. the Medical University of Vienna.

Worg will pay continuous efforts on allergy immunotherapy and more fields beyond allergy.